Repligen (RGEN) Q3 2026 Earnings Call Transcript

Repligen reported $209M in Q3 2026 revenue, up 12.5% organically, with expanded margins. The company raised full-year guidance, including $24M from BioLife acquisition. Capital equipment orders rose mid-teens YoY, and services grew over 20%. Biopharma drove growth, while CDMOs declined. Repligen expects to exceed $1B in revenue in 2027, with Asia Pacific showing strong growth.

Original reporting
Published Oct 27, 2026, 3:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 4:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Repligen (RGEN) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$RGENBullishMed
01

Why it matters

The guidance raise is a fresh, material development that can move the stock in the short term.

02

Market read

Repligen's updated guidance provides a clear trading catalyst for the stock and may influence peer valuations in the bioprocessing sector.

03

What to watch

Potential headwinds from slower capital equipment demand and foreign exchange volatility could temper growth.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Repligen's Q3 earnings call highlighted organic revenue growth, margin expansion, and the recent BioLife acquisition, which is now factored into its 2026 outlook.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 2026 revenue of $209M and raised full-year 2026 guidance after its BioLife acquisition.

Expected impact

likely upside as investors price in higher revenue and margin outlook

Evidence & confidence

The company disclosed fresh guidance with concrete numbers that exceed prior expectations, a material catalyst for the stock.

Market effects

Bioprocessing and biopharma equipment sector may see renewed investor interest on the back of Repligen's growth outlook.

Positive for U.S. biotech and life‑science stocks, especially peers with exposure to cell‑therapy manufacturing.

Limited to the niche bioprocessing market; no broad macro impact.

Counterpoint

If integration costs exceed expectations, the guidance lift could be overstated, leading to downside pressure.

Key entities

  • Repligen

    U.S. bioprocessing firm (ticker RGEN) reporting earnings and guidance.

  • BioLife

    Acquired bioprocessing business now contributing to Repligen's outlook.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.